Does Insurance Cover GLP-1? Your 2026 Plan-by-Plan Guide to Wegovy, Zepbound, and Medicare Coverage

Does insurance cover GLP-1? Yes — sometimes — and the answer flips depending on what you’re treating, not just which drug you’re on. In 2026, most U.S. insurance plans cover GLP-1 medications when prescribed for type 2 diabetes, cardiovascular risk reduction, or moderate-to-severe sleep apnea. Coverage for weight loss alone (Wegovy, Zepbound, Foundayo, Saxenda) is far narrower, and it tightened on January 1, 2026 — several major plans dropped or restricted weight-loss GLP-1 coverage on that date.

Coverage by plan type at a glance

Does insurance cover GLP-1 medications? The four levers that decide

Coverage isn’t decided by the drug. It’s decided by four things working together. Most readers ask “does my insurance cover Wegovy?” and walk away with a confused answer because the question itself is too narrow. The same drug, prescribed for a different reason, on a different plan, with different documentation, gets a completely different answer.

Two coworkers can both have BCBS, both ask for Wegovy, and get opposite answers — because their employers picked different formularies, or because one prescription supports an additional indication that the other doesn’t.

So the question to ask isn’t “do you cover GLP-1?” The question is:

“Do you cover [specific drug] under my pharmacy benefit for [specific diagnosis], and what prior authorization criteria apply?”

That single rephrase will unlock more useful answers from your insurer than anything else on this page.

Which GLP-1 medications are most likely to be covered

The drugs most likely to be covered depend on the diagnosis, not the brand alone. Diabetes-labeled GLP-1s tend to be covered for type 2 diabetes. Obesity-labeled drugs tend to be covered only when the plan includes anti-obesity medications, or when the prescription matches a non-weight-loss FDA-approved use.

What qualifies you for GLP-1 insurance coverage?

Plan qualification depends on diagnosis, FDA-approved use, BMI and comorbidity criteria, formulary placement, prior authorization rules, and supporting documentation. No single number qualifies you on its own.

Does private (commercial / employer) insurance cover GLP-1 in 2026?

Sometimes — and 2026 has been a tougher year, not a better one. Per KFF’s 2025 Employer Health Benefits Survey, about 19% of large firms (200+ workers) covered GLP-1s for weight loss; 57% did not, and 24% were unsure. Coverage was more common at very large employers — roughly 43% of firms with 5,000+ workers included weight-loss GLP-1 coverage. Among firms that covered them, about a third required participation in a dietitian, case manager, therapy, or lifestyle program.

Several plan-level changes hit in early 2026:

• Mass General Brigham Health Plan dropped GLP-1 coverage for weight management for fully insured commercial members on January 1, 2026. Coverage continues for type 2 diabetes.
• Health New England dropped Saxenda, Wegovy, and Zepbound coverage for weight loss on January 1, 2026.
• Blue Cross Blue Shield of Massachusetts announced GLP-1 coverage except for type 2 diabetes ends upon plan renewal starting January 1, 2026.
• Fallon Health Community Care plans no longer cover weight-loss medications as of January 1, 2026.
• CVS Caremark removed Zepbound from its standard formulary on July 1, 2025 in favor of Wegovy and Saxenda. Employers can still negotiate custom coverage.

2026 commercial-insurer landscape (verified examples)

The honest read: the brand on the front of your insurance card matters less than what your plan booklet says. Two BCBS plans can be a world apart. Two UnitedHealthcare plans can be a world apart. The only reliable answer is the one your specific plan documents give you.

Ro’s coverage checker calls your insurer directly and emails you a personalized coverage report. Free, no Ro membership required.

Does Medicare cover GLP-1 in 2026? (The Bridge was just extended through 2027)

Medicare can cover GLP-1s through two distinct paths. Standard Part D may cover GLP-1s for FDA-approved or otherwise coverable non-weight-loss uses — for example, Zepbound for moderate-to-severe OSA and Wegovy for cardiovascular risk reduction are typically handled through standard Part D, not the Bridge. The newer Medicare GLP-1 Bridge — a temporary nationwide demonstration starting July 1, 2026 — covers Wegovy, Zepbound (KwikPen), and Foundayo for obesity at a $50 monthly copay for eligible Part D enrollees.

Are you eligible for the Bridge?

CMS published three distinct eligibility tiers. The provider must attest the drug is prescribed for excess body weight reduction, the beneficiary must be 18 or older, and must meet one of:

Which drugs are Bridge-eligible

The fine print most pages skip

• The $50 Bridge copay does NOT count toward your Part D deductible, TrOOP, or annual out-of-pocket cap.
• Low-Income Subsidy (LIS) cannot be applied to the $50 Bridge copay — the program operates outside the standard Part D benefit.
• Pharmacies and Part D plans don’t need to opt in. CMS is running this through Humana as the nationwide central processor.
• Coupons and manufacturer copay cards generally cannot be combined with Bridge pricing.

Medicare coverage outside the Bridge

You may not need the Bridge at all. Standard Part D may cover:

• GLP-1s for type 2 diabetes: Ozempic, Mounjaro, Trulicity, Rybelsus, Bydureon, Victoza, Byetta — subject to plan formulary, often with PA.
• Wegovy injection for cardiovascular risk reduction in adults with established CV disease and obesity or overweight — through standard Part D as a non-weight-loss indication.
• Zepbound for moderate-to-severe OSA in adults with obesity — through standard Part D.
• Wegovy injection for MASH with moderate-to-advanced liver fibrosis — covered through standard Part D since the August 2025 FDA approval.

Does Medicaid cover GLP-1? It depends on your state

Medicaid coverage of GLP-1s for weight loss is state-by-state, and the trend in 2026 was contraction, not expansion. As of January 2026, 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service — down from 16 in October 2025, after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage. KFF says Medicaid coverage is required for drugs prescribed for medically accepted indications such as diabetes, certain cardiovascular uses, and OSA — while obesity-treatment coverage remains optional for states.

What changed in late 2025 and early 2026

• California (Medi-Cal) eliminated GLP-1 weight-loss coverage for adults 21+ effective January 1, 2026. Wegovy, Zepbound, and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for weight-loss indications.
• Pennsylvania eliminated obesity-treatment coverage of GLP-1s effective January 1, 2026, citing the rise in GLP-1 prescription spending from $223M in 2022 to $650M in 2024. Coverage continues for type 2 diabetes and other medically-accepted indications.
• New Hampshire and South Carolina also eliminated weight-loss GLP-1 coverage in late 2025 / early 2026.
• North Carolina briefly eliminated coverage in October 2025 due to a state budget stalemate, then reinstated it in December 2025. NC is back on the “covering” list as of January 2026.
• Michigan issued updated pharmacy guidance restricting GLP-1 coverage for weight loss with transition rules for existing patients. Verify against the current MDHHS pharmacy bulletin.

If your state isn’t covering, you still have three real paths

1. Medically accepted indication coverage. If your prescription is for type 2 diabetes (Ozempic, Mounjaro, Rybelsus), cardiovascular risk reduction (Wegovy injection), or OSA (Zepbound), Medicaid generally covers it.
2. Manufacturer patient assistance programs. Novo Nordisk’s PAP and Eli Lilly’s PAP both provide free or reduced-cost medication for income-qualifying patients.
3. Cash-pay routes. 2026 prices are dramatically lower than they were two years ago. FDA-approved oral GLP-1s now start at $149/month.

Does Marketplace, TRICARE, VA, or IHS coverage include GLP-1?

Coverage in these buckets is the most variable and the most often misunderstood.

Why was my GLP-1 denied? The denial-letter decoder

A denial isn’t always a “no” — it’s often a “not yet, with this paperwork.” Per KFF Marketplace data, fewer than 1% of denied claims are ever appealed, and when they are, insurers upheld about 66% of denials — meaning roughly one in three appealed denials are overturned in the patient’s favor. The math is on your side if you actually file.

The most important distinction: prior authorization denial (criteria can be met with paperwork) vs. a plan exclusion (the benefit doesn’t exist). Internal appeals work great for the first; they rarely overturn the second.

For a deeper, denial-type-specific appeal walkthrough, see our How to get insurance to cover GLP-1 tactical guide.

How to get prior authorization approved on the first try

Many fixable denials happen because the file is incomplete, not because the patient is ineligible. A clean PA submission generally needs five things — exact requirements vary by plan, so always confirm your insurer’s specific criteria first.

1. 1
   Recent BMI documentation. Many plans require recent BMI/weight documentation (some require two measurements 30+ days apart, both within the last 90 days). Ask your insurer their specific rule.
2. 2
   ICD-10 diagnosis codes. Not just “obesity” — the actual code, plus comorbidity codes (E11 for type 2 diabetes, I10 for hypertension, E78 for dyslipidemia, G47.33 for OSA, etc.). Plain text in the chart doesn’t trigger automated approvals; codes do.
3. 3
   Supporting labs. A1C for diabetes/prediabetes, lipid panel for dyslipidemia, sleep study for OSA, CMP, TSH, and (for women of childbearing age) a pregnancy test.
4. 4
   A real Letter of Medical Necessity. Not a template with your name dropped in. The LMN should address: why GLP-1 is appropriate, expected benefit beyond weight loss alone, why alternatives are insufficient or were tried, and the monitoring plan.
5. 5
   The right drug on the formulary tier the plan prefers. If the plan prefers Wegovy, the preferred option may be easier than fighting a forced switch. If you medically need Zepbound (OSA, prior semaglutide failure), document that and request the exception.

How much does a GLP-1 cost with insurance — and without?

With coverage, your out-of-pocket cost can be as low as $25/month. Without it, FDA-approved cash-pay options now start at $149/month for oral GLP-1s and $199–$349/month for injection options. The cash-pay landscape changed dramatically in late 2025 and early 2026 — and it’s the single biggest piece of news that hasn’t fully reached people who got priced out two years ago.

2026 cash-pay price map (verified Feb–Apr 2026)

What if your plan flat-out excludes GLP-1s for weight loss?

A coverage checker can’t override a hard plan exclusion. If your employer-sponsored plan excludes anti-obesity medications as a category, no insurance concierge can force the plan to cover something it didn’t buy. Ro’s insurance concierge will fight a denial; it can’t rewrite a plan booklet. Pretending otherwise wastes your time.

If that’s where you are, you have four real options:

1. Indication change. If your clinical picture supports it, your prescriber may be able to write the prescription for a covered indication: Wegovy injection for cardiovascular risk reduction in eligible patients, Zepbound for OSA, or Wegovy injection for MASH. This only works if you actually have one of these conditions and your prescriber documents it truthfully.
2. HR escalation. Your employer can add a weight-management rider at next plan-year renewal. The HR ask: “Does our plan exclude anti-obesity medications entirely, or is there a path to coverage with documentation?”
3. Plan switch at open enrollment. Look for “anti-obesity medication coverage” or “weight management benefit” in the SBC.
4. Cash-pay. With Wegovy pill at $149–$299/month and Foundayo starting at $149/month, the cash-pay route is no longer the financial cliff it was in 2024.

Are compounded GLP-1 medications covered by insurance?

No, in nearly every case. Compounded GLP-1 preparations are not on insurer formularies, and they are not FDA-approved finished products. Insurance pays for FDA-approved drugs on the plan’s formulary; that excludes compounded preparations as a category.

Two practical points:

1. Insurance won’t pay for compounded GLP-1s. If insurance coverage is your priority, compounded is not your path.
2. Compounded GLP-1s may be HSA/FSA-eligible when prescribed by a licensed provider for a diagnosed medical condition. Confirm with your plan administrator.

The fastest way to find out if your specific plan covers GLP-1

Three options, in order of speed. Most people overcomplicate this and waste a week.

HSA, FSA, and GLP-1: what’s eligible, what gets denied

GLP-1 medications prescribed by a licensed provider for a diagnosed medical condition are generally HSA- and FSA-eligible. This includes Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, Saxenda, and Foundayo. The IRS standard from Publication 502: the cost of “diagnosis, cure, mitigation, treatment, or prevention of disease” is a qualified medical expense. This is not tax advice — keep your receipts and confirm with your HSA/FSA administrator.

• HSAs generally don’t require additional documentation at checkout. Save your receipts and the LMN if your provider issued one.
• FSAs more often require a Letter of Medical Necessity, especially for weight-loss prescriptions. Get one proactively.
• Compounded GLP-1s may be reimbursable when prescribed for a diagnosed medical condition. Confirm with your FSA/HSA administrator before assuming.
• Stacking HSA/FSA + cash-pay is the most underused win here. A $299/month Wegovy pill paid through an HSA at a 25% effective tax bracket is a real cost of about $224/month — not far off the $50 Bridge copay.

Frequently asked questions about GLP-1 insurance coverage

What we actually verified for this guide

Health and insurance content moves fast. Transparency is a requirement on this page.

Why we built this page

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We built this page because “does insurance cover GLP-1?” is the wrong question to walk into a pharmacy with. The right question is “does my plan cover this drug for this diagnosis, and what does the prior authorization need?” We laid out the answer by plan type, decoded the most common denial language, gave you the cash-pay map, and pointed you to free tools where they exist.

We earn commissions from some of the providers covered on this page (Ro and Sesame Care included). Affiliate relationships do not change the content or the order of this guide — those are driven by search intent and verified facts.